| 000 -LEADER |
|---|
| fixed length control field |
04666nam a22005295i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-1-59745-184-0 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20161121230840.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100301s2008 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781597451840 |
| -- |
978-1-59745-184-0 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-1-59745-184-0 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED062000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Antiangiogenic Agents in Cancer Therapy |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Beverly A. Teicher, Lee M. Ellis. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
Second Edition. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Totowa, NJ : |
| Name of producer, publisher, distributor, manufacturer |
Humana Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XVIII, 559 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer research. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Surgical oncology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Surgical Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology/Toxicology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Teicher, Beverly A. |
| Relator term |
editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ellis, Lee M. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9781588298706 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Cancer Drug Discovery and Development |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-59745-184-0 |
| 912 ## - |
|---|
| -- |
ZDB-2-SME |
